Last $0.0050 USD
Change Today +0.0011 / 28.21%
Volume 18.4K
PHRX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

pharmagen inc (PHRX) Snapshot

Open
$0.0036
Previous Close
$0.0039
Day High
$0.0050
Day Low
$0.0036
52 Week High
06/12/14 - $0.02
52 Week Low
09/17/14 - $0.0022
Market Cap
2.6M
Average Volume 10 Days
542.8K
EPS TTM
--
Shares Outstanding
517.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMAGEN INC (PHRX)

Related News

No related news articles were found.

pharmagen inc (PHRX) Related Businessweek News

No Related Businessweek News Found

pharmagen inc (PHRX) Details

Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes. The company also manufactures and distributes health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin. In addition, it sells traditional pharmaceuticals to its distribution customers, such as antibiotics, vaccines, and other oral and injectable pharmaceuticals; and specializes in the formulation of drugs. The company was formerly known as Sunpeaks Ventures, Inc. and changed its name to Pharmagen, Inc. in January 2013. Pharmagen, Inc. is based in Silver Spring, Maryland.

24 Employees
Last Reported Date: 03/31/14

pharmagen inc (PHRX) Top Compensated Officers

Founder and Vice Chairman
Total Annual Compensation: $150.0K
Compensation as of Fiscal Year 2013.

pharmagen inc (PHRX) Key Developments

Pharmagen, Inc. Files Form 15

Pharmagen, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.

Pharmagen, Inc. Announces Management Changes

Pharmagen, Inc. announced that on June 30, 2014, Richard A. Wolpow resigned as chairman of the board and director; Danny M. Barnes, David S. Rowley and Stephen M. Perry resigned as directors; Boyd P. Relac resigned as chief operating officer and secretary; and Russell Skibsted resigned as executive vice president, chief financial officer and principal financial officer.

Pharmagen, Inc. Announces Executive Changes

Pharmagen, Inc. announced that effective June 10, 2014, Mackie Barch, President and Chief Executive Officer, resigned those positions and was appointed as Founder and Vice-Chairman of the board of directors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHRX:US $0.01 USD +0.0011

PHRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHRX.
View Industry Companies
 

Industry Analysis

PHRX

Industry Average

Valuation PHRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAGEN INC, please visit www.pharmageninc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.